{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:52:09Z","timestamp":1790189529365,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008868","name":"Jiangsu Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["BE2023780"],"award-info":[{"award-number":["BE2023780"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["BK20220716"],"award-info":[{"award-number":["BK20220716"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370194"],"award-info":[{"award-number":["82370194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200887"],"award-info":[{"award-number":["82200887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M711404"],"award-info":[{"award-number":["2022M711404"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M741463"],"award-info":[{"award-number":["2023M741463"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.canlet.2024.216877","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T21:58:26Z","timestamp":1712959106000},"page":"216877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma"],"prefix":"10.1016","volume":"591","author":[{"given":"Jin-Hua","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Rui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ran","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.canlet.2024.216877_bib1","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canlet.2024.216877_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.canlet.2024.216877_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.canlet.2024.216877_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216877_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221080738","article-title":"Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)","volume":"13","author":"Tbakhi","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"14","key":"10.1016\/j.canlet.2024.216877_bib6","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.216877_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216877_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2024.216877_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.canlet.2024.216877_bib10","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.7150\/thno.62378","article-title":"Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.canlet.2024.216877_bib11","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/0008-5472.CAN-22-0917","article-title":"Metabolic reprogramming in hematologic malignancies: advances and clinical perspectives","volume":"82","author":"Yu","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.216877_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2024.216877_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.18878","article-title":"MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma","volume":"202","author":"Liang","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.canlet.2024.216877_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065493","article-title":"Metabolic reprogramming and potential therapeutic targets in lymphoma","volume":"24","author":"Pang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2024.216877_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2024.216877_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-022-00292-z","article-title":"Targeting metabolic reprogramming in chronic lymphocytic leukemia","volume":"11","author":"Nie","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216877_bib17","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.canlet.2024.216877_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01530-21","article-title":"Epstein-barr virus induced cytidine metabolism roles in transformed B-cell growth and survival","volume":"12","author":"Liang","year":"2021","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.canlet.2024.216877_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.gendis.2022.07.003","article-title":"EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: potential role in EBV lymphomagenesis","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.canlet.2024.216877_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216616","article-title":"CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy","volume":"583","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2024.216877_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.18878","article-title":"MYC-induced cytidine metabolism regulates survival and drug resistance via cGas-STING pathway in mantle cell lymphoma","volume":"202","author":"Liang","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2024.216877_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114842","article-title":"Medicinal chemistry strategies targeting PRMT5 for cancer therapy","volume":"244","author":"Fu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.canlet.2024.216877_bib23","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2024.216877_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112252","article-title":"Targeting protein arginine methyltransferase 5 in cancers: roles, inhibitors and mechanisms","volume":"144","author":"Chen","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.canlet.2024.216877_bib25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.canlet.2024.216877_bib26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.2022019419","article-title":"PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma","volume":"142","author":"Sloan","year":"2023","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.canlet.2024.216877_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-023-00799-6","article-title":"Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations","volume":"13","author":"Che","year":"2023","journal-title":"Blood Cancer J."},{"issue":"20","key":"10.1016\/j.canlet.2024.216877_bib28","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1182\/bloodadvances.2023009906","article-title":"PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma","volume":"7","author":"Brown-Burke","year":"2023","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.canlet.2024.216877_bib29","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1074\/jbc.RA119.007640","article-title":"Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT\/\u03b2-catenin and AKT\/GSK3\u03b2 proliferative signaling","volume":"294","author":"Chung","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.canlet.2024.216877_bib30","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"Pal","year":"2007","journal-title":"Embo j"},{"issue":"8","key":"10.1016\/j.canlet.2024.216877_bib31","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1111\/cas.14988","article-title":"An AKT\/PRMT5\/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.canlet.2024.216877_bib32","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/0008-5472.CAN-15-1766","article-title":"Arginine methylation of SREBP1a via PRMT5 promotes de novo lipogenesis and tumor growth","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.216877_bib33","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/ijc.31590","article-title":"Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma","volume":"143","author":"Gao","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2024.216877_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.gendis.2019.06.002","article-title":"PRMT5 in gene regulation and hematologic malignancies","volume":"6","author":"Zhu","year":"2019","journal-title":"Genes Dis"},{"issue":"12","key":"10.1016\/j.canlet.2024.216877_bib35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2024.216877_bib36","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1038\/ncomms7428","article-title":"PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2024.216877_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"Tarighat","year":"2016","journal-title":"Leukemia"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:11:25Z","timestamp":1784945485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":37,"alternative-id":["S0304383524002702"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216877","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216877"}}